Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Partial Epilepsies: later-stage trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Partial Epilepsies: 3 US clinical trials tracked, none currently recruiting.
Partial Epilepsies is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is UCB Pharma, running 2 of these trials.
Enrollment posture brief
Registry condition partial-epilepsies
OPEN 0 | RECR 0% | LATE 2 | EARLY 1 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Partial Epilepsies has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Partial Epilepsies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Partial Epilepsies is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures
UCB Pharma
NCT00955357
To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
UCB Pharma
NCT00552305
Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
UCB Biosciences
NCT00655486
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Partial Epilepsies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Partial Epilepsies trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Partial Epilepsies page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Partial Epilepsies trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- UCB Pharma sponsors the most Partial Epilepsies trials on record, review their full trial history before evaluating a specific study. See UCB Pharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Partial Epilepsies condition card totals 3 registered trials; most-linked intervention lacosamide; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.